News for Gossamer Bio, Inc. (GOSS)

[url="]Gossamer Bio, Inc.[/url] (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutini

Gossamer Bio (GOSS) grants stock options to new non-executive employees. The stock options cover 69,875 shares priced at $1.26 each. Options will ves

MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Con

**media[632753]**

**media[631374]**

Cash and Cash Equivalents: $257.9 million at the end of Q1 2025.Revenue: $9.9 million for Q1 2025.R&D Expenses: $38 million for Q1 2025, up from $32.4 million

May 15, 2025 / 08:30PM GMTOperator Good afternoon, ladies and gentlemen. Welcome to the Gossamer Bio Q1 2025 earnings call. I will now turn the program over to

Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ETCompany ParticipantsBryan Giraudo - COO & CFOFaheem Hasnain -...

[url="]Gossamer Bio, Inc.[/url] (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutini

Revenue: $9.9 million, significantly surpassing the estimated $4.07 million for the quarter.Earnings Per Share (EPS): Reported a net loss of $0.16 per share, b

We recently published a list of the 11 Best Penny Stocks to Invest in Under $1. In this article, we are going to take a look at where Gossamer Bio Inc.

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Gossamer Bio, Inc. (NASDAQ:GOSS) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where Gossamer Bio, Inc.

**media[568943]**

Revenue: Achieved $9.38 million for the quarter, surpassing the estimated $6.83 million.Earnings Per Share (EPS): Reported a net loss of $0.15 per share, bette

[url="]Gossamer Bio, Inc.[/url] (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutini

Gossamer Bio (GOSS) delivered earnings and revenue surprises of 11.76% and 19.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

[url="]Gossamer Bio, Inc.[/url] (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutini